MENU
OUR PRODUCTS
MOBILE APPS
GENERAL INFO
Help
© 2013-2025 All rights reserved. Tickeron Inc.
TRVI
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Trevi Therapeutics (TRVI) Earnings Date & Reports

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis... Show more

A.I. Advisor
published Earnings

TRVI is expected to report earnings to rise 19.89% to -10 cents per share on November 05

Trevi Therapeutics TRVI Stock Earnings Reports
Q3'25
Est.
$-0.11
Q2'25
Beat
by $0.01
Q1'25
Beat
by $0.04
Q4'24
Beat
by $0.01
Q3'24
Missed
by $0.01
The last earnings report on August 07 showed earnings per share of -9 cents, beating the estimate of -10 cents. With 292.49K shares outstanding, the current market capitalization sits at 903.42M.
View a ticker or compare two or three
GO
VS
Compare
VS
Compare
TRVI
TickeronSetup
Buy or SellView
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View Trends For TRVI
(Try 14 days for Free)
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. TRVI showed earnings on August 07, 2025. You can read more about the earnings report here.
View AI-Driven Trading
A.I. Advisor
published General Information

General Information

a developer and manufacturer of neurological products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
195 Church Street
Phone
+1 203 304-2499
Employees
25
Web
https://www.trevitherapeutics.com